Quantcast

Latest lung cancer Stories

2014-06-05 16:27:21

LONDON, June 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/squamous_cell_carcinoma_global_clinical_trials_review.html Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Squamous...

2014-06-03 12:27:34

Institute of Cancer Research Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals. Scientists announce a previously unknown link between lung cancer and a particular BRCA2 defect, occurring in around 2 per cent of the population, in research published in Nature Genetics today (Sunday). The defect in BRCA2 - best known for its role in breast cancer - increases the risk of...

2014-06-03 11:22:42

University of Colorado Denver A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma...

2014-06-03 08:27:38

All proceeds from sale of Jewel's song to support LUNG FORCE; CVS Caremark Continues Commitment as National Presenting Sponsor of LUNG FORCE with In-Store Promotion in June CHICAGO, June 3, 2014 /PRNewswire/ -- Grammy-nominated singer-songwriter Jewel unveiled a new song, "Sing On," in support of LUNG FORCE, a new initiative to make lung cancer in women a public health priority, drive policy change and increase research funding. LUNG FORCE is a national movement led by the American...

2014-06-02 23:04:58

BCC Research Tarceva® Forecast, a strategic investment product designed to provide critical market data for the pharmaceutical lung cancer drug Tarceva. Wellesley, Mass., (PRWEB) June 02, 2014 BCC Research (http://www.bccresearch.com) is pleased to announce BCC Research Tarceva® Forecast, a strategic investment product designed to provide critical market data for the pharmaceutical lung cancer drug Tarceva. Tarceva (Astellas Pharma) is a once-daily, oral, non-chemotherapy...

2014-06-02 22:55:01

University of Colorado Denver A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. The current study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other...

2014-06-02 22:51:56

University of Colorado Denver Volatile organic compounds in exhaled breath show presence and stage of lung cancer Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present....

2014-06-02 20:22:44

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA((TM)) (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract...

2014-06-02 16:26:19

- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing Zykadia((TM) )(ceritinib, previously known as LDK378) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time. Results...

2014-06-02 16:25:16

Cancers characterized by DICER1 genetic defect are advancing new approach to cancer treatments, cures MINNEAPOLIS, June 2, 2014 /PRNewswire/ -- Recent findings by researchers from the International Pleuropulmonary Blastoma (PPB) Registry and International Ovarian and Testicular Stromal (OTST) Tumor Registry, both based at Children's Hospitals and Clinics of Minnesota, have advanced the potential for early diagnosis and proactive treatment of children in families affected by...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »
Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related